Mr. Mike Withrow reports

NOTICE OF DEFAULT - UPDATE

Arev Life Sciences Global Corp. did not file its annual financial statements, and management's discussion and analysis for the fiscal year ended Dec. 31, 2022, by the filing deadline of April 30, 2023, and, as a result, is in default of its obligations under Part 4 of National Instrument 51-102 -- Continuous Disclosure Obligations.

The company has requested from the applicable Canadian securities regulators that a management cease trade order related to the company's securities be imposed against some or all of the persons who have been directors, officers or insiders of the company. A management cease trade order was issued on May 3, 2023. This order does not generally affect the ability of persons who have not been directors, officers or insiders of the company to trade the company's securities.

The company intends to satisfy the alternative information guidelines set out National Policy 12-203 -- Cease Trade Orders for Continuous Disclosure Default by filing biweekly default status reports, as required, until such time as the financial statements and MD&A are filed.

The company advises that there are no material changes to the information contained in the default announcement or particulars of the failure, and there is no material information concerning the affairs of the company that has not been generally disclosed. The company does not anticipate any subsequent defaults under National Instrument 51-102 -- Continuous Disclosure Obligations.

About Arev Life Sciences Global Corp.

The company is a fully integrated enterprise with competencies in: (1) extraction of compounds for consumption and topical use; (2) clinical nutrition; and (3) a technology platform called Medicine Merchant. The company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The company's business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The company continues in the product development and precommercialization stage. Arev is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. Arev is a member of both BIOTECanada and the Biotechnology Innovation Organization (BIO).

We seek Safe Harbor.